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Bothmelatonin and electroacupuncture (EA) have been suggested to be effective treatments against stroke. However, it is unknown
whether a combination of these two therapies could be beneficial against transient focal cerebral ischemia. The present study
investigated the effects of pretreatment of a combination of melatonin and EA in a rat model of transient middle cerebral artery
occlusion (MCAO).After pretreatment ofmelatonin plus EA (MEA), transientMCAOwas induced for 90minutes inmale Sprague-
Dawley (SD) rats. The neurological deficit score, brain infarct volume, cerebral edema ratio, neuronal inflammation, and apoptosis
were evaluated 24 hours after transientMCAO.Theexpression of related inflammatory and apoptoticmediators in the brainwas also
investigated. The results showed that MEA improved neurological outcome, reduced brain infarct volume, and inhibited neuronal
inflammation as well as apoptosis 24 hours after transient MCAO. The beneficial effects may derive from downregulation of
proinflammatory and proapoptotic mediators and upregulation of antiapoptotic mediators.Thus, these results suggest a preventive
effect of pretreatment of MEA on transient focal cerebral ischemia.
1. Introduction
Stroke is a serious cerebral vascular event with increasing
prevalence worldwide especially in the society with aging of
the population, and ischemic stroke is the most common
type. Intravenous thrombolysis using recombinant tissue
plasminogen activator (rtPA) is the only approved treatment
[1]. Many neuroprotectants have been investigated; they were
effective in animals but not in stroke patients [2–4]. Owing to
the narrow therapeutic time window [5, 6] and a substantial
risk of hemorrhagic complications, clinical use of rtPA is
limited to a small number of stroke patients [7].Thus, broader
attention to integrated therapeutics has been advocated
repeatedly for treating ischemic stroke to increase the chance
of success [4, 8, 9]. Moreover, most of the current thera-
pies are focused on posttreatment after cerebral ischemia.
However, accumulating lines of evidence have demonstrated
the efficacy of pretreatment therapies which could induce
neuroprotection against cerebral ischemic injury.
Melatonin is a potent antioxidant and free radical scav-
enger with few toxicological effects in animals and humans
[10]. An adequate amount of evidence indicates its effective
protection against stroke in different models and animal
species [11–16]. Although the beneficial effect of melatonin
as well as its related mechanisms can be further investigated,
some clinical scientists have suggested that melatonin, com-
bined with other neuroprotectants or proven therapies, may
enhance the treatment effects or extend the therapeutic time
window. Moreover, it is worthy of conducting phase II or III
clinical trials of melatonin in stroke patients [11].
Acupuncture has been widely applied to stroke patients
in East Asia for centuries. It is easy to manipulate, econom-
ical and safe. EA is a combination of traditional acupunc-
ture (manual acupuncture) and electrical stimulation. It
is believed to enhance the efficacy of acupuncture and is
currently used to treat various kinds of illnesses [17, 18].
Though the research in this field using western scientific
methods is still in the very beginning, increasing clinical and
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experimental publications have provided physiological rather
than metaphysical evidence to confirm and explain both the
phenomena andmechanisms of acupuncture [18–22]. Never-
theless, the beneficial effects of acupuncture on stroke recov-
ery remain controversial.Thismay be due to poor experimen-
tal design, inappropriate controls, and small sample size [23].
In traditional Chinese medical theory, acupuncturing at
the acupoints along the meridian of Yangming (stomach
meridian) is especially efficient for the treatment of flaccid
paralysis. Zusanli (ST 36) is the classical acupoint recorded
in the ancient Chinese medical literature for thousands of
years and has been frequently investigated in scientific study
for treating stroke. Moreover, the literature review shows
that ST 36 and xiajuxu (ST 39) are the mostly investigated
acupoints including animal and clinical studies [24, 25].Their
beneficial effects on ischemic stroke have also been elucidated
and reported. In the present study, both ST 36 and ST 39 were
chosen for EA treatment.
Evidence from animal research in acute cerebral ischemia
shows that combinations of neuroprotectants might be more
efficacious than the single agent given alone. Both melatonin
and EA have been suggested to be effective treatments
against cerebral ischemia. However, it is unknown whether a
combination of these two therapies could be beneficial against
focal cerebral ischemia.
There are increasing lines of evidence that pretreatment of
neuroprotectants effectively improves neurological outcome
and interferes with mechanisms of brain injury [26, 27]. In
the present study, pretreatment of MEA was conducted to
examine whether MEA could exert neuroprotection against
transient cerebral ischemia and which mechanisms are
behind it.
2. Materials and Methods
2.1. Animals and Surgical Procedures. Adult male SD rats,
weighing between 250 and 280 g, were obtained from the
Laboratory Animal Unit, The University of Hong Kong, and
kept under 12 hours light/12 hours dark conditions. The
experiments were performed according to the institutional
regulation and guidelines approved by the Committee on the
Use of Live Animals in Teaching and Research (CULATR),
The University of Hong Kong.
Transient focal cerebral ischemia was induced using
right-sided transient endovascular MCAO [28–30] with
reperfusion. In brief, the right common carotid artery (CCA),
right external carotid artery (ECA), and right internal carotid
artery (ICA) were exposed through a midline cervical inci-
sion.With the right ECAdissected free and its distal branches
coagulated (Bipolar Electric Coagulation, GN60, Aesculap
AG and Co., Tuttlingen, Germany), a 5-o silk suture was
loosely tied around the ECA stump, and microclips were
temporarily placed at both the right CCA and right ICA.
A piece of silicone coated 4-o (5mm coating length with
0.35–0.37mm diameter) nylon suture (Doccol Corporation,
Redlands, CA; Cat no. 4037) was inserted into the lumen
of right ECA stump, and the 5-o silk suture was gently
tightened to prevent bleeding. Next the nylon suture was
gently advanced through right ICA into the right anterior
cerebral artery (ACA) to occlude the right middle cerebral
artery (MCA) at its origin. The rats were subjected to 90
minutes of focal cerebral ischemia, and then the silicon
coated 4-o nylon suture was carefully withdrawn to permit
reperfusion.Thewoundswere closed using 4-o nylon sutures,
and the rats were allowed to fully recover from the anesthesia
before returning to their cages.
The focal cerebral ischemia was confirmed by obvi-
ous changes of regional cerebral blood flow (rCBF) on
laser Doppler flow meter (MBF3D, Moor instruments, Ltd.,
Devon, UK). A burr hole of 2mm diameter was made on
the right side of skull at 5mm lateral and 2mm posterior
to the bregma with the aid of a stereotaxic device (SR-6N;
Narishige Scientific Instrument Laboratory, Tokyo, Japan).
Next the laser probe was glued onto the burr hole. Steady-
state baseline values were documented before induction
of cerebral ischemia, and all rCBF were normalized and
expressed as percentages of baseline values.
2.2. Experimental Groups. Rats were assigned to one of two
groups: control group and MEA group.
(1) Control group: the vehicle, normal saline containing
3% dimethyl sulfoxide (DMSO, Sigma-Aldrich, St.
Louis, MO, USA), was given via an intraperitoneal
(i.p.) injection 30 minutes before transient MCAO.
Sham EA treatment was given once per day and
started 6 days before transient MCAO. During the
sham EA treatment, rats were anesthetized with an
i.p. injection of sodium pentobarbital at a dose of
40mg/kg without real EA stimulation.
(2) MEA group: a single dose of melatonin (10mg/kg)
was given via an i.p. injection 30 minutes before
transient MCAO. Whilst under anesthesia, EA treat-
ment was given once per day and started 6 days
before transient MCAO. Melatonin (Sigma-Aldrich)
was dissolved in 1mL of normal saline containing 3%
DMSO.
A schematic overview of the experimental procedures
was summarized (Figure 1). All the rats were sacrificed 24
hours after transient MCAO for determination of brain
infarct volume, cerebral edema ratio, and tissue processing.
Neurological outcome of rats was evaluated before sacrifice.
2.3. Manipulation of EA Treatment. A thirty-minute real or
sham EA treatment was applied each time at different time
points (daily administration during the 6 days before tran-
sientMCAO)with aHan’s acupoint nerve stimulator (HANS-
200, Jisheng Medical Science and Technology Co., Ltd., Nan-
jing, China). The stimulation intensity was 0.5mA, and the
stimulation frequency was 2Hz. Four stainless steel acupunc-
ture needles (0.25mm in diameter, 25mm in length; Huatuo,
Suzhou Medical Instruments Factory, Suzhou, China) were
inserted bilaterally with a 4mm depth into two acupoints, ST
36 and ST 39. A Han’s acupoint stimulator was connected to
the inserted acupuncture needles. The location of these two
acupoints was based on the transpositional acupoint system
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Figure 1: Schematic overview of the experimental procedures in a rat model of transient MCAO. Two groups are included in the experiment.
The horizontal line represents time. A single i.p. injection of the vehicle and melatonin was given 30 minutes before transient MCAO in
control and MEA groups, respectively. Whilst the rats were under anesthesia, sham and real EA were given daily 6 days before transient
MCAO in the sham EA group and EA group, respectively. All the rats were killed 24 hours after transient MCAO for determination of brain
infarct volume, cerebral edema ration and tissue processing.
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Figure 2: Diagram of the acupoints location and acupuncture manipulation in the rat. ST 35, dubi, is located at the depression lateral to the
patella ligament; ST 36, zusanli, is located at proximal one-fifth point on the line from ST 35 to the anterior side of ankle crease; ST 39, xiajuxu,
is located at proximal 3 fifths point on the line from ST 35 to the anterior side of ankle crease.
in a ratmodel [29], whichwasmodified from a former animal
transpositional acupoint system [30]. ST 36 is located on the
line from dubi (ST 35) to the ankle crease of hind limb and is
at proximal one-fifth point of the line. ST 39 is at proximal
three-fifths point of the line between ST 35 and the ankle
crease. ST 35 is located at the depression on the lateral side
of the patella ligament of the hind leg (Figure 2).
2.4. Neurological Behavior Assessment. Neurological deficit
scoring system (NDSS) test (Table 1) was used to quantify
neurological behavior 24 hours after transient MCAO and
was done by a blinded observer. NDSS test was adapted from
a validated scoring system [31, 32]. The higher the score, the
more severe was the injury. All the rats were trained before
operation to be familiar with the testing environment.
2.5. Brain Infarct Volume and Cerebral Edema Ratio Measure-
ment. Brain infarct volume of the right cerebral hemisphere
was measured 24 hours after transient MCAO. Under deep
anesthesia after an i.p. injection of pentobarbital at 100mg/kg,
the brains were removed and cut into coronal slices of
2mm thick using a rodent brain matrix (World Precision
Instruments, Inc., Sarasota, FL). After reaction with 2% 2,3,5-
triphenyltetrazolium chloride (TTC; Sigma-Aldrich) for 20
minutes at 37∘C, the slices of brain were fixed in 10%
formalin (pH 7.4). Both sides of each slice were scanned
for measurement of both hemisphere and infarct volume
using a computer assisted image analysis system (Image J Ver.
1.36b, NIH, USA). Unstained areas represented the ischemic
lesions. A cerebral edema ratio was calculated from the ratio
of the volume of the right hemisphere to the left hemisphere.
To compensate for the effect of brain swelling, the actual
(corrected) infarct volume was calculated via dividing the
volume of infarction by the edema ratio. Brain infarct volume
was expressed as a percentage of the contralateral hemisphere
[31, 32].
2.6. Histological Examination. At 24 hours after transient
MCAO, rats were deeply anesthetized with an i.p. injection
of pentobarbital at 100mg/kg and transcardially perfused
with 0.9% normal saline first and then with ice-cold 4%
paraformaldehyde (Sigma-Aldrich) in 0.1Mphosphate buffer
(PB; pH 7.5). Coronal brain sections at a thickness of 4 𝜇m
were made from 2mm anterior and 1mm posterior to the
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Table 1: Neurological deficit scoring system (NDSS) test.
Points
Motor tests
Spontaneous activity
Approaches at least three sides of cage 0
Approaches at least one rim but not all sides of cage 1
Slight movement 2
No movement 3
Floor walking
Straight path 0
Curvilinear path 1
Walks only in circles 2
No walking 3
Sensorimotor tests
Raising rat by the tail
Flexion of forelimb 1
Flexion of hindlimb 1
Thorax twisting 1
Left limbs placing task
Forelimb
Normal performance 0
Delayed (less than 2 seconds) 1
Delayed (at least 5 seconds) and/or incomplete performance 2
No performance 3
Hindlimb
Normal performance 0
Delayed (less than 2 seconds) 1
Delayed (at least 5 seconds) and/or incomplete performance 2
No performance 3
Beam balance tests
Walks on the beam 0
Grasps side of beam 1
Hugs the beam and one limb falls down from the beam 2
Hugs the beam and two limbs fall down from the beam or spins on beam
(>60 s) 3
Attempts to balance on the beam but falls off (>40 s) 4
Attempts to balance on the beam but falls off (>20 s) 5
Falls off: with no attempt to balance or hang on the beam (<20 s) 6
Maximal number of point is 21. Points were awarded for inability of performing the tasks. The higher the score, the more severe is the injury.
bregma and stained with hematoxylin and eosin (HE). Ter-
minal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay was also performed using an in situ cell death
detection kit (Roche, Indianapolis, IN). Brain sections near
bregma level 0 were chosen for quantification. The number
of TUNEL-positive cells from five selected regions within the
infarction and penumbra in the right cerebral hemisphere
was counted, respectively. The number of positive cells was
counted by a blinded investigator and expressed as number
per squaremillimeter.The section slides were analyzed under
light microscope (Axio Vision Control, Carl Zeiss, Munich,
Germany).
2.7. Western Blot Analysis. Western blot analysis was used
to determine the expression of inflammatory and apoptotic
mediators. Rats from the two groups were decapitated 24
hours after transient MCAO. The infarct region (between
2mm anterior and 1mm posterior to the bregma) of the
right cerebral hemisphere was dissected on ice. Samples were
placed in radioimmune precipitation assay (RIPA) lysis buffer
containing a protease inhibitor cocktail and a phosphatase
inhibitor cocktail (Sigma-Aldrich). After sonication for 5
seconds, the lysate was kept on ice for 30 minutes. After
20 minutes centrifugation at 12,000 g, the supernatants were
collected. The protein concentration was determined using
a Bradford protein assay kit (Bio-Rad, Hercules, CA). Forty
𝜇g of total protein was mixed with protein loading buffer
and separated using 10–15% sodiumdodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE). After electrophore-
sis, the proteins were transferred to polyvinylidene difluoride
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Figure 3:Neurological deficit scoring system (NDSS) score 24 hours
after transient MCAO. Data are expressed as mean ± SEM (𝑛 = 14).
∗
𝑃 < 0.05, compared with the control group. The neurological
function was significantly improved by MEA pretreatment.
(PVDF)membrane (Bio-Rad) at 4∘C. After blocking nonspe-
cific binding sites on the membrane with 5% nonfat milk in
Tris-HCL-based buffered saline with 0.1% Tween 20 (TBST;
Sigma-Aldrich) at pH 7.4 for 1 hour at room temperature,
and the membranes were incubated at 4∘C overnight with
primary antibodies, including tumor necrosis factor-alpha
(TNF-𝛼) (1 : 200 dilution; Santa Cruz Biotechnology, Dallas,
TX), cyclooxygenase 2 (COX-2) (1 : 500 dilution; Santa Cruz
Biotechnology), B-cell lymphoma 2 (Bcl-2) (1 : 500 dilution;
Santa Cruz Biotechnology), Bcl-2-associated X protein (Bax)
(1 : 500 dilution; Santa Cruz Biotechnology), and 𝛽-actin
(1 : 2000 dilution; Santa Cruz Biotechnology). After three
washes (15minutes per time)withTBST, themembraneswere
incubated with a horseradish peroxidase-conjugated goat
secondary antibody (anti-mouse, 1 : 7000 dilution; SantaCruz
Biotechnology; or anti-rabbit, 1 : 7000 dilution; Santa Cruz
Biotechnology) at room temperature for 1 hour. After three
washes with TBST, the protein bands were visualized using
advanced chemoluminescence (GE Healthcare Life Sciences,
Hong Kong), recorded by GelDoc-2000 Imagine System
(Bio-Rad), and the relative intensity of protein expressionwas
quantified using Quantity One software (Bio-Rad).
2.8. Data Analysis. All the data were analyzed using SPSS
(Window version 13.0; SPSS Inc., Chicago, IL) and expressed
as mean ± SEM. One sample t-test was used to detect a
significant change in rCBF data from the baseline value at
different time points in each group. Data were compared
using Student’s t-test. 𝑃 < 0.05 was used to infer statistical
significance.
3. Results
3.1. Relative rCBF. During transient cerebral ischemia, the
normalized rCBF was significantly decreased; there was no
statistically significant difference at different time points
within the same group. During reperfusion, the normalized
rCBF returned towards baseline values; there was no sta-
tistically significant difference within the same group. No
significant difference was observed between the control and
MEA groups at the same time points during ischemia and
reperfusion (𝑃 > 0.05), as shown in Tables 2, 3, and 4.
3.2. Effect of MEA on Neurological Deficit Score. When
compared with the control group (14.07±0.43), neurological
function was significantly improved by MEA pretreatment
(12.37 ± 0.50) 24 hours after transient MCAO (𝑃 < 0.05),
as shown in Figure 3.
3.3. Effect of MEA on Brain Infarct Volume and Cerebral
Edema Ratio. Figure 4(a) summarizes the representative
brain slices after reaction with TTC 24 hours after transient
MCAO. The right cerebral infarct was evident as the whitish
region. Figure 4(b) summarizes the computer assisted image
analysis data revealing the relative brain infarct volumes in
the two groups 24 hours after transient cerebral ischemia.
The relative infarct volume was expressed as mean ± SEM.
When compared with the control group (36.5 ± 2.6%), MEA
pretreatment (27.1± 3.7%) significantly decreased the infarct
volume by 25.7% (𝑃 < 0.05). Figure 5 summarizes the data
revealing the cerebral edema ratio in the two groups 24 hours
after transient cerebral ischemia. There was no significant
difference between the two groups (𝑃 > 0.05).
3.4. Effect of MEA on Histological Changes of Brain Inflam-
mation 24 Hours after Transient MCAO. Brain section near
bregma level 0 stained with HE revealed the histological
changes 24 hours after transient MCAO (Figure 6). In the
control group, many necrotic neurons and infiltrated neu-
trophils were seen in the infarcted cortex after transient
MCAO. In rats pretreated with MEA, neutrophil infiltration
within the ischemic cerebral cortex was suppressed.
3.5. Effect of MEA on Histological Changes of Brain Apoptosis
24 Hours after Transient MCAO. Five regions within the
cortex and penumbra were respectively selected for cell
counting on the right cerebral hemisphere. Many TUNEL-
positive cells were seen within the infarct and penumbral
areas of the right cerebral hemisphere in the control group
24 hours after transient MCAO. In the MEA pretreatment
group, increase in the number of TUNEL-positive cell within
the ischemic cerebral cortex and penumbra was significantly
reduced (Figures 7 and 8).
3.6. Effect of MEA on Protein Expression of Inflammatory
Mediators 24 Hours after Transient MCAO. The expression
of inflammatory mediators, including TNF-𝛼 (Figure 9) and
COX-2 (Figure 10), was investigated using western blot anal-
ysis 24 hours after transient MCAO. Immunoblots of these
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Figure 4: Brain infarct volume measurement 24 hours after transient MCAO. (a) Digital photographs of the 2mm thick coronal brain slices
between the bregma levels +4mm (anterior) and −6mm (posterior) in control and MEA groups 24 hours after right-sided endovascular
transient MCAO. TTC reaction showed viable brain tissue in red and infarcted brain tissue in white. (b) Quantitative analyses of brain infarct
volume 24 hours after transient MCAO. The data are expressed as percentage of the contralateral hemispheric volume (mean ± SEM, in %,
𝑛 = 14). ∗Indicates the significant difference between the control group and MEA group (𝑃 < 0.05).
Table 2: Normalized regional cerebral blood flow (rCBF, %) at different time points in relation to the onset of transient MCAO with MEA
pretreatment in the study on neurological function and brain infarct volume in rats.
Group (number of rats) Before MCAO Onset ofMCAO
30min after
MCAO
60min after
MCAO
Onset of
reperfusion
30min after
reperfusion
Control (14) 100 23.3 ± 1.7 23.4 ± 1.6 25.2 ± 1.7 87.0 ± 3.3 99.4 ± 4.0
MEA (14) 100 24.8 ± 1.4 25.1 ± 1.8 26.8 ± 2.2 88.4 ± 4.2 94.1 ± 5.1
Data are expressed as mean ± SEM. Normalized rCBF dropped to less than 30% during transient MCAO and returned to more than 70% at the onset of
reperfusion. There was no statistically significant difference between the control and MEA groups at the same time points (𝑃 > 0.05).
Table 3: Normalized regional cerebral blood flow (rCBF, %) at different time points in relation to the onset of transient MCAO with MEA
pretreatment in the study on tissue apoptosis in the right cerebral hemisphere of the rats.
Group (number of rats) Before MCAO Onset ofMCAO
30min after
MCAO
60min after
MCAO
Onset of
reperfusion
30min after
reperfusion
Control (5) 100 24.6 ± 1.6 25.5 ± 1.5 27.2 ± 1.7 96.5 ± 6.2 98.0 ± 5.5
MEA (5) 100 23.3 ± 2.1 24.4 ± 1.9 26.2 ± 2.3 104.3 ± 6.8 102.1 ± 10.2
Data are expressed as mean ± SEM. Normalized rCBF dropped to less than 30% during transient MCAO and returned to more than 70% at the onset of
reperfusion. There was no statistically significant difference between the control and MEA groups at the same time points (𝑃 > 0.05).
Table 4: Normalized regional cerebral blood flow (rCBF, %) at different time points in relation to the onset of transient MCAO with MEA
pretreatment in the study on western blot in the right cerebral hemisphere of the rats.
Group (number of rats) Before MCAO Onset ofMCAO
30min after
MCAO
60min after
MCAO
Onset of
reperfusion
30min after
reperfusion
Control (3) 100 23.2 ± 2.2 24.8 ± 2.6 26.2 ± 2.0 105.7 ± 6.6 106.4 ± 8.8
MEA (3) 100 25.2 ± 2.6 25.7 ± 2.5 27.6 ± 2.8 107.5 ± 9.1 114.9 ± 11.1
Data are expressed as mean ± SEM. Normalized rCBF dropped to less than 30% during transient MCAO and returned to more than 70% at the onset of
reperfusion. There was no statistically significant difference between the control and MEA groups at the same time points (𝑃 > 0.05).
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Figure 5: Data of cerebral edema ratio 24 hours after transient
MCAO. Data are expressed as mean ± SEM (𝑛 = 14). Student’s
t-test reveals no significant difference in cerebral edema ratio 24
hours after transient MCAO between the control and MEA group
(𝑃 > 0.05).
Control MEA
Figure 6: Photomicrographs of HE-stained brain sections near
bregma level 0 24 hours after right-sided transient MCAO (mag-
nification: 400x). In the control group, neutrophil infiltration was
mainly present in the infarcted cortex. Neutrophil infiltration in the
ischemic cerebral cortex was suppressed by the MEA pretreatment
group 24 hours after transient MCAO.
inflammatory mediators were obtained from right cerebral
hemisphere. When compared with the control group, MEA
pretreatment significantly decreased the upregulated protein
expression of TNF-𝛼 and COX-2 (𝑃 < 0.01).
3.7. Effect of MEA on Protein Expression of Bcl-2 Family
Proteins 24 Hours after Transient MCAO. The expression of
Bax and Bcl-2 was investigated using western blot anal-
ysis (Figures 11 and 12) 24 hours after transient MCAO.
Immunoblots of these proteinswere obtained from right cere-
bral hemisphere.When compared with the control group, the
relative protein expression of Bax was significantly decreased
by MEA pretreatment (𝑃 < 0.05). The protein expression
of Bcl-2 was significantly increased by MEA when compared
with the control group (𝑃 < 0.01).
4. Discussion
Increasing evidence shows that pretreatment with various
kinds of neuroprotectants induces beneficial effects against
stroke in animal models; however, many of them have
limitations and adverse effects that may prevent the clinical
application in patients [33, 34]. Although it is suggested that
therapeutics for prevention of first and recurrent stroke, such
as blood pressure control and anti-thrombosis, are highly
recommended in clinical practice [35, 36], some of these
drugs, like antiplatelets and anticoagulants, have a risk of
causing hemorrhage. Therefore, it is desirable to develop not
only efficient but also safe strategies aiming at preventing
cerebral ischemia as well as reducing ischemic injury. A
previous study in our lab (unpublished data) has shown that
posttreatment of MEA may induce neuroprotective effect in
transientMCAO.Thepresent studywas performed to explore
whether pretreatment of the combined therapy may prevent
the brain from cerebral ischemic injury.
Firstly, the effect of MEA pretreatment on NDSS score,
brain infarct volume, and cerebral edema ratio was investi-
gated.The data showed that when compared with the control
group, pretreatment of MEA significantly improved neuro-
logical functions 24 hours after transientMCAO.Meanwhile,
MEA reduced the brain infarct volume by 25.7% 24 hours
after transient MCAO. No significant changes in the cerebral
edema ratio were observed. There were no significant differ-
ences in rCBF data during cerebral ischemia and reperfusion.
Secondly, the effect of MEA pretreatment on histological
and cellular inflammation after transient ischemic stroke
was examined. HE staining of brain sections shows that
many necrotic neurons and infiltrated neutrophils were
seen in the infarcted cortex after transient MCAO. In rats
pretreated with MEA, neutrophil infiltration within the
ischemic cerebral cortex was suppressed. In addition, MEA
pretreatment reduced the upregulated protein expression of
two proinflammatory mediators, TNF-𝛼 and COX-2, in the
ischemic right cerebral hemisphere 24 hours after transient
MCAO. These results indicate the anti-inflammatory effects
of MEA pretreatment of against transient MCAO.
Thirdly, the effect of MEA pretreatment on histological
and cellular apoptosis after transient ischemic stroke was
evaluated. In the present study, TUNEL staining of brain
sections shows that there were many TUNEL-positive cells
within the ischemic infarction and penumbra of the right
cerebral hemisphere in the control group 24 hours after
transient MCAO. The number of TUNEL-positive cells was
significantly decreased in the same areas by MEA pretreat-
ment 24 hours after transient MCAO.
Moreover, MEA pretreatment decreased the level of
proapoptotic protein Bax and increased the level of anti-
apoptotic protein Bcl-2 24 hours after transient MCAOwhen
compared to the control group. The present data suggest
the antiapoptotic effect of MEA pretreatment in transient
MCAO.
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Figure 7: Apoptosis in the infarcted cortex of right ischemic cerebral hemisphere 24 hours after transient MCAO. (a) Representative images
of TUNEL staining in the infarcted cortex of right ischemic cerebral hemisphere 24 hours after transient MCAO.The brown staining within
the nuclei reveals TUNEL-positive cells. (b) Quantitative analysis of TUNEL-positive cells. Data are expressed as means ± SEM (𝑛 = 5).
∗
𝑃 < 0.05, compared with the control group. The number of TUNEL-positive cells was significantly decreased by MEA pretreatment. Scale
bar = 100𝜇m.
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Figure 8: Apoptosis in the penumbra of right ischemic cerebral hemisphere 24 hours after transient MCAO. (a) Representative images
of TUNEL staining in the penumbra of right ischemic cerebral hemisphere 24 hours after transient MCAO. The brown staining within the
nuclei reveals TUNEL-positive cells. (b) Quantitative analysis of TUNEL-positive cells. Data are expressed asmeans± SEM (𝑛 = 5). ∗𝑃 < 0.01,
compared with the control group.The number of TUNEL-positive cells was significantly decreased byMEApretreatment. Scale bar = 100 𝜇m.
Previous research indicates that inflammatory response is
induced in the cerebral infarct and its surrounding areas after
cerebral ischemia [37]. Various proinflammatory mediators,
such as TNF-𝛼 and COX-2, are upregulated after stroke.
These mediators play critical roles in the process of neu-
ronal survival following brain injury [38, 39]. Inhibition of
TNF-𝛼 reduced the brain infarct volume and suppressed
the inflammatory responses in a mouse model of transient
cerebral ischemia [40]. Overexpression of COX-2 may exac-
erbate brain damage [41]. According to the present data, the
neuroprotection with regard to neurological outcome and
brain infarct volumemay be partly due to the inhibitory effect
of MEA on TNF-𝛼 and COX-2.
The damage resulting from cerebral ischemia is con-
stituted by two principal zones: infarct core and ischemic
penumbra. After ischemic stroke, neuronal apoptosis occurs
mainly in the penumbral area [42]. In particular after tran-
sient focal ischemia, apoptosis may be a contributing factor
to the final infarct volume [43]. According to the present
data, the number of TUNEL-positive cells was significantly
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Figure 9: Protein expression of TNF-𝛼 24 hours after transient MCAO in different groups. (a) Representative immunoblots of TNF-𝛼 in the
right cerebral hemisphere of different groups 24 hours after transient MCAO. (b) Semiquantitative analysis of protein expression of TNF-𝛼.
Data are expressed as means ± SEM (𝑛 = 3). ∗𝑃 < 0.01, compared with the control group. The relative expression of TNF-𝛼 was significantly
inhibited by MEA pretreatment.
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Figure 10: Protein expression of COX-2 24 hours after transient MCAO in different groups. (a) Representative immunoblots of COX-2 in the
right cerebral hemisphere of different groups 24 hours after transient MCAO. (b) Semiquantitative analysis of protein expression of COX-2.
Data are expressed as means ± SEM (𝑛 = 3). ∗𝑃 < 0.01, compared with the control group. The relative expression of COX-2 was significantly
decreased by MEA pretreatment.
decreased in the penumbral area by MEA pretreatment
24 hours after transient MCAO. This finding may partly
explain the result of infarct volume reduction after MEA
pretreatment. In addition, Bax and Bcl-2 are suggested to
be distinct regulators of apoptosis in the early stages of
stroke [44]. Upregulation of Bax and downregulation of Bcl-
2 are repeatedly observed in the penumbral area following
cerebral ischemia [45]. Bax inhibition results in neuropro-
tection against stroke [46]. Decreased expression of Bcl-2
leads to increased oxidative stress [46, 47]. The present data
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Figure 11: Protein expression of Bax 24 hours after transient MCAO in different groups. (a) Representative immunoblots of Bax in the right
cerebral hemisphere of different groups 24 hours after transient MCAO. (b) Semiquantitative analysis of protein expression of Bax. Data are
expressed as means ± SEM (𝑛 = 3). ∗𝑃 < 0.05, compared with the control group. The relative expression of Bax was significantly decreased
by MEA pretreatment.
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Figure 12: Protein expression of Bcl-2 24 hours after transient MCAO in different groups. (a) Representative immunoblots of Bcl-2 in the
right cerebral hemisphere of different groups 24 hours after transient MCAO. (b) Semiquantitative analysis of protein expression of Bcl-2.
Data are expressed as means ± SEM (𝑛 = 3). ∗𝑃 < 0.01, compared with the control group. The relative expression of Bcl-2 was significantly
increased by MEA pretreatment.
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indicate the antiapoptotic effect of MEA pretreatment via
downregulation of Bax and upregulation of Bcl-2.
In conclusion, this study provides some preliminary data
with regard to the effect of MEA pretreatment on transient
focal cerebral ischemia. The present results indicate that
MEA pretreatment may induce a neuroprotection against
transient MCAO in terms of improved neurological function
and decreased brain infarct volume.The beneficial effects are
partly mediated by anti-inflammation and antiapoptosis.
Acknowledgment
This research was supported by the Committee on Research
and Conference Grants (200907176032), The University of
Hong Kong, Hong Kong.
References
[1] W. Hacke, M. Kaste, E. Bluhmki et al., “Thrombolysis with
alteplase 3 to 4.5 hours after acute ischemic stroke,” The New
England Journal ofMedicine, vol. 359, no. 13, pp. 1317–1329, 2008.
[2] Y.D.Cheng, L. Al-Khoury, and J. A. Zivin, “Neuroprotection for
ischemic stroke: two decades of success and failure,” NeuroRx,
vol. 1, no. 1, pp. 36–45, 2004.
[3] A. I. Faden and B. Stoica, “Neuroprotection: challenges and
opportunities,” Archives of Neurology, vol. 64, no. 6, pp. 794–
800, 2007.
[4] L. Zhang, Z. G. Zhang, and M. Chopp, “The neurovascular
unit and combination treatment strategies for stroke,” Trends in
Pharmacological Sciences, vol. 33, no. 8, pp. 415–422, 2012.
[5] O. Adeoye, R. Hornung, P. Khatri, and D. Kleindorfer, “Recom-
binant tissue-type plasminogen activator use for ischemic
stroke in the united states: a doubling of treatment rates over
the course of 5 years,” Stroke, vol. 42, no. 7, pp. 1952–1955, 2011.
[6] G. C. Fonarow, E. E. Smith, J. L. Saver et al., “Timeliness of
tissue-type plasminogen activator therapy in acute ischemic
stroke: patient characteristics, hospital factors, and outcomes
associated with door-to-needle times within 60 minutes,” Cir-
culation, vol. 123, no. 7, pp. 750–758, 2011.
[7] M. Lee, J. L. Saver, J. R. Alger et al., “Blood-brain barrier
permeability derangements in posterior circulation ischemic
stroke: frequency and relation to hemorrhagic transformation,”
Journal of the Neurological Sciences, vol. 313, no. 1-2, pp. 142–146,
2012.
[8] J. M. Hallenbeck and K. U. Frerichs, “Stroke therapy: it may be
time for an integrated approach,” Archives of Neurology, vol. 50,
no. 7, pp. 768–770, 1993.
[9] J. Hart, “Poststroke recovery: emerging complementary thera-
pies,” Alternative and Complementary Therapies, vol. 16, no. 5,
pp. 277–280, 2010.
[10] B. Guardiola-Lemaˆıtre, “Toxicology of melatonin,” Journal of
Biological Rhythms, vol. 12, no. 6, pp. 697–706, 1997.
[11] R. T. F. Cheung, “The utility of melatonin in reducing cerebral
damage resulting from ischemia and reperfusion,” Journal of
Pineal Research, vol. 34, no. 3, pp. 153–160, 2003.
[12] P. Giusti, M. Gusella, M. Lipartiti et al., “Melatonin protects
primary cultures of cerebellar granule neurons from kainate
but not from-methyl-d-aspartate excitotoxicity,” Experimental
Neurology, vol. 131, no. 1, pp. 39–46, 1995.
[13] H. Manev, U. Z. Tolga, A. Kharlamov, and J. Joo, “Increased
brain damage after stroke or excitotoxic seizures in melatonin-
deficient rats,”The FASEB Journal, vol. 10, no. 13, pp. 1546–1551,
1996.
[14] C. V. Borlongan, M. Yamamoto, N. Takei et al., “Glial cell sur-
vival is enhanced during melatonin-induced neuroprotection
against cerebral ischemia,” The FASEB Journal, vol. 14, no. 10,
pp. 1307–1317, 2000.
[15] K. Sinha, M. N. Degaonkar, N. R. Jagannathan, and Y. K. Gupta,
“Effect of melatonin on ischemia reperfusion injury induced by
middle cerebral artery occlusion in rats,” European Journal of
Pharmacology, vol. 428, no. 2, pp. 185–192, 2001.
[16] H. Lin and E.-J. Lee, “Effects of melatonin in experimental
stroke models in acute, sub-acute, and chronic stages,” Neu-
ropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 157–162,
2009.
[17] S. Lee, G. H. Choi, C. H. Lee et al., “Exploration of new
electroacupuncture needle material,” Evidence-Based Comple-
mentary and Alternative Medicine, vol. 2012, Article ID 612545,
10 pages, 2012.
[18] G. A. Ulett, S. Han, and J. Han, “Electroacupuncture: mecha-
nisms and clinical application,”Biological Psychiatry, vol. 44, no.
2, pp. 129–138, 1998.
[19] B. Pomeranz, G. Stux, and C. Han, Scientific Bases of Acupunc-
ture, Springer, New York, NY, USA, 1989.
[20] H. M. Langevin, P. M. Wayne, H. MacPherson et al., “Para-
doxes in acupuncture research: strategies for moving forward,”
Evidence-Based Complementary and Alternative Medicine, vol.
2011, Article ID 180805, 11 pages, 2011.
[21] J. Park, K. Linde, E. Manheimer et al., “The status and future
of acupuncture clinical research,” Journal of Alternative and
Complementary Medicine, vol. 14, no. 7, pp. 871–881, 2008.
[22] H. MacPherson, R. Nahin, C. Paterson, C. M. Cassidy, G. T.
Lewith, and R. Hammerschlag, “Developments in acupuncture
research: big-picture perspectives from the leading edge,” Jour-
nal of Alternative and Complementary Medicine, vol. 14, no. 7,
pp. 883–887, 2008.
[23] H. M. Wu, J. L. Tang, X. P. Lin et al., “Acupuncture for stroke
rehabilitation,”The Cochrane Library, no. 1, pp. 1–25, 2009.
[24] W. Chen, H. Gu, W. Ma et al., “Multicentral randomized
controlled study on effects of acupuncture at Zusanli (ST 36)
and Xuanzhong (GB 39) on cerebrovascular function in the
patient of ischemic stroke,” Zhongguo Zhen Jiu, vol. 26, no. 12,
pp. 851–853, 2006.
[25] W. Gong, T. Zhang, L. Cui, Y. Yang, and X. Sun, “Electro-
acupuncture at Zusanli (ST 36) to improve lower extremity
motor function in sensory disturbance patients with cerebral
stroke: a randomized controlled study of 240 cases,” Neural
Regeneration Research, vol. 4, no. 11, pp. 935–940, 2009.
[26] T. Kondoh, Y. Ueta, and K. Torii, “Pre-treatment of
adrenomedullin suppresses cerebral edema caused by transient
focal cerebral ischemia in rats detected by magnetic resonance
imaging,” Brain Research Bulletin, vol. 84, no. 1, pp. 69–74, 2011.
[27] K. Schmerbach, T. Pfab, Y. Zhao et al., “Effects of aliskiren
on stroke in rats expressing human renin and angiotensinogen
genes,” PLoS ONE, vol. 5, no. 11, Article ID e15052, 2010.
[28] L. Belayev, O. F. Alonso, R. Busto,W. Zhao, andM. D. Ginsberg,
“Middle cerebral artery occlusion in the rat by intraluminal
suture: neurological and pathological evaluation of an improved
model,” Stroke, vol. 27, no. 9, pp. 1616–1623, 1996.
12 Evidence-Based Complementary and Alternative Medicine
[29] M. Khan, C. Elango, M. A. Ansari, I. Singh, and A. K. Singh,
“Caffeic acid phenethyl ester reduces neurovascular inflamma-
tion and protects rat brain following transient focal cerebral
ischemia,” Journal of Neurochemistry, vol. 102, no. 2, pp. 365–
377, 2007.
[30] E. Z. Longa, P. R. Weinstein, S. Carlson, and R. Cummins,
“Reversible middle cerebral artery occlusion without craniec-
tomy in rats,” Stroke, vol. 20, no. 1, pp. 84–91, 1989.
[31] J. H. Garcia, S.Wagner, K.-F. Liu, X.-J. Hu, and J. P. Mohr, “Neu-
rological deficit and extent of neuronal necrosis attributable to
middle cerebral artery occlusion in rats: statistical validation,”
Stroke, vol. 26, no. 4, pp. 627–635, 1995.
[32] D. Reglodi, A. Tama´s, and I. Lengva´ri, “Examination of sensori-
motor performance following middle cerebral artery occlusion
in rats,”Brain Research Bulletin, vol. 59, no. 6, pp. 459–466, 2003.
[33] J. Montaner, C. A. Molina, J. Monasterio et al., “Matrix
metalloproteinase-9 pretreatment level predicts intracranial
hemorrhagic complications after thrombolysis in human
stroke,” Circulation, vol. 107, no. 4, pp. 598–603, 2003.
[34] M. Krikov, C. Thone-Reineke, S. Mu¨ller, A. Villringer, and T.
Unger, “Candesartan but not ramipril pretreatment improves
outcome after stroke and stimulates neurotrophin BNDF/TrkB
system in rats,” Journal of Hypertension, vol. 26, no. 3, pp. 544–
552, 2008.
[35] G. Tsivgoulis, M. Saqqur, V. K. Sharma, A. Y. Lao, M. D.
Hill, and A. V. Alexandrov, “Association of pretreatment blood
pressure with tissue plasminogen activator-induced arterial
recanalization in acute ischemic stroke,” Stroke, vol. 38, no. 3,
pp. 961–966, 2007.
[36] P. B. Gorelick, “Stroke prevention therapy beyond antithrom-
botics: unifying mechanisms in ischemic stroke pathogenesis
and implications for therapy: an invited review,” Stroke, vol. 33,
no. 3, pp. 862–875, 2002.
[37] G. Stoll, S. Jander, and M. Schroeter, “Inflammation and glial
responses in ischemic brain lesions,” Progress in Neurobiology,
vol. 56, no. 2, pp. 149–171, 1998.
[38] J. M. Hallenbeck, “The many faces of tumor necrosis factor in
stroke,” Nature Medicine, vol. 8, no. 12, pp. 1363–1368, 2002.
[39] S. Nogawa, F. Zhang, M. Elizabeth Ross, and C. Iadecola,
“Cyclo-oxygenase-2 gene expression in neurons contributes to
ischemic brain damage,”The Journal of Neuroscience, vol. 17, no.
8, pp. 2746–2755, 1997.
[40] G. Yang, C. Gong, Z. Qin, W. Ye, Y. Mao, and A. L. Bertz,
“Inhibition of TNF𝛼 attenuates infarct volume and ICAM-1
expression in ischemic mouse brain,” NeuroReport, vol. 9, no.
9, pp. 2131–2134, 1998.
[41] S. Dore´, T. Otsuka, T. Mito et al., “Neuronal overexpression
of cyclooxygenase-2 increases cerebral infarction,” Annals of
Neurology, vol. 54, no. 2, pp. 155–162, 2003.
[42] Y. Li, M. Chopp, N. Jiang, F. Yao, and C. Zaloga, “Temporal
profile of in situ DNA fragmentation after transient middle
cerebral artery occlusion in the rat,” Journal of Cerebral Blood
Flow and Metabolism, vol. 15, no. 3, pp. 389–397, 1995.
[43] C. Y. Hsu, G. An, J. S. Liu, J. J. Xue, Y. Y. He, and T. N. Lin,
“Expression of immediate early gene and growth factor mRNAs
in a focal cerebral ischemia model in the rat,” Stroke, vol. 24,
supplement 12, pp. I78–I81, 1993.
[44] D. E. Merry and S. J. Korsmeyer, “Bcl-2 gene family in the
nervous system,” Annual Review of Neuroscience, vol. 20, no. 1,
pp. 245–267, 1997.
[45] S. Krajewski, J. K. Mai, M. Krajewska, M. Sikorska, M. J.
Mossakowski, and J. C. Reed, “Upregulation of bax protein
levels in neurons following cerebral ischemia,” The Journal of
Neuroscience, vol. 15, no. 10, pp. 6364–6376, 1995.
[46] C. M. Troy, D. Derossi, A. Prochiantz, L. A. Greene, and M.
L. Shelanski, “Downregulation of Cu/Zn superoxide dismutase
leads to cell death via the nitric oxide-peroxynitrite pathway,”
The Journal of Neuroscience, vol. 16, no. 1, pp. 253–261, 1996.
[47] A. Hochman, H. Sternin, S. Gorodin et al., “Enhanced oxidative
stress and altered antioxidants in brains of Bcl-2-deficientmice,”
Journal of Neurochemistry, vol. 71, no. 2, pp. 741–748, 2002.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
